Search results: Sage Journals

Available accessResearch articleFirst published April, 2024

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario

Andrea Zovi, Ruggero Lasala, Francesco Ferrara [...]

Hospital Pharmacy

Open accessResearch articleFirst published 2026

Migraine treatment and work absence trends before and after introduction of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs): A nationwide Swedish register study

Johan A. Liseth Hansen, Meghan Skira, Knut Reidar Wangen

Cephalalgia Reports

Open accessResearch articleFirst published 2025

Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study

Alessia Bellotti, Caterina Podella, Paola Sarchielli

Cephalalgia Reports

Open accessResearch articleFirst published 2025

Severe acute allergic reaction after switching anti-calcitonin gene-related peptide monoclonal antibodies: A case report

Ikko Wada, Atsushi Shima, Yuu Tatsuoka [...]

Cephalalgia Reports

Open accessResearch articleFirst published July, 2026

Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study

Misaki Kamogawa, Masakazu Higurashi, Akito Oshima [...]

Cephalalgia

Open accessResearch articleFirst published February, 2026

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week,prospective multicenter study (the TACHIS study)

Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano [...]

Cephalalgia

Open accessResearch articleFirst published May, 2023

Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month,single-center,observational real-world study in Japan

Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina [...]

Cephalalgia

Open accessResearch articleFirst published June, 2023

The short-term effects of CGRP monoclonal antibodies on bone turnover: A prospective cohort study

Jason C. Ray, Shoshana Sztal-Mazer, Josephine Baker [...]

Cephalalgia

Free accessReview articleFirst published March, 2019

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

David W Dodick

Cephalalgia

Open accessResearch articleFirst published June, 2025

Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study

Sait Ashina, Gilwan Kim, E. Jolanda Muenzel [...]

Cephalalgia

Available accessResearch articleFirst published April, 2024

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario

Andrea Zovi, Ruggero Lasala, Francesco Ferrara [...]

Hospital Pharmacy

Open accessResearch articleFirst published 2026

Migraine treatment and work absence trends before and after introduction of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs): A nationwide Swedish register study

Johan A. Liseth Hansen, Meghan Skira, Knut Reidar Wangen

Cephalalgia Reports

Open accessResearch articleFirst published 2025

Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study

Alessia Bellotti, Caterina Podella, Paola Sarchielli

Cephalalgia Reports

Open accessResearch articleFirst published 2025

Severe acute allergic reaction after switching anti-calcitonin gene-related peptide monoclonal antibodies: A case report

Ikko Wada, Atsushi Shima, Yuu Tatsuoka [...]

Cephalalgia Reports

Open accessResearch articleFirst published July, 2026

Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study

Misaki Kamogawa, Masakazu Higurashi, Akito Oshima [...]

Cephalalgia

Open accessResearch articleFirst published February, 2026

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week,prospective multicenter study (the TACHIS study)

Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano [...]

Cephalalgia

Open accessResearch articleFirst published May, 2023

Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month,single-center,observational real-world study in Japan

Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina [...]

Cephalalgia

Open accessResearch articleFirst published June, 2023

The short-term effects of CGRP monoclonal antibodies on bone turnover: A prospective cohort study

Jason C. Ray, Shoshana Sztal-Mazer, Josephine Baker [...]

Cephalalgia

Free accessReview articleFirst published March, 2019

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

David W Dodick

Cephalalgia

Open accessResearch articleFirst published June, 2025

Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study

Sait Ashina, Gilwan Kim, E. Jolanda Muenzel [...]

Cephalalgia